Current issues in the management of acute promyelocytic leukemia

Annals of Hematology

Volumn 79, Issue 5, 1999, Pages 227-238

  Slack, James L ^a   Rusiniak, Michael E ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Acute promyelocytic leukemia; Cancer

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; HISTONE; HYBRID PROTEIN; RETINOIC ACID; RETINOIC ACID RECEPTOR;

ACUTE MYELOBLASTIC LEUKEMIA; APOPTOSIS; BONE MARROW CELL; CELL DIFFERENTIATION; CELL MATURATION; DEACETYLATION; GENE EXPRESSION; GENE MUTATION; HUMAN; MAINTENANCE THERAPY; PRIORITY JOURNAL; PROMOTER REGION; PROMYELOCYTE; REMISSION; REVIEW;

HUMANS; LEUKEMIA, PROMYELOCYTIC, ACUTE; RECEPTORS, RETINOIC ACID;

EID: 0342368618     PISSN: 09395555     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002770050585     Document Type: Review

References (72)

1. Lo Coco F, Nervi C, Avvisati G, Mandelli F (1998) Acute promyelocytic leukemia: a curable disease. Leukemia 12 : 1866-1880
2. Redner RL, Wang J, Liu JM (1999) Chromatin remodeling and leukemia: new therapeutic paradigms. Blood 94 : 417-428
3. Melnick A, Licht JD (1999) Deconstructing a disease: RAR-alpha, its fusion partners, and their roles in the pathogenesis of acute promyelocytic leukemia. Blood 93 : 3167-3215
4. Lin RJ, Egan DA, Evans RM (1999) Molecular genetics of acute promyelocytic leukemia. Trends Genet 15 : 179-184
5. Nason-Burchenal K, Takle G, Pace U, Flynn S, Allopenna J, Martin P, George ST, Goldberg AR, Dmitrovsky E (1998) Targeting the PML/RAR alpha translocation product triggers apoptosis in promyelocytic leukemia cells. Oncogene 17 : 1759-1768
6. Wang ZG, Ruggero D, Ronchetti S, Zhong S, Gaboli M, Rivi R, Pandolfi PP (1998) PML is essential for multiple apoptotic pathways. Nat Genet 20 : 266-272
7. Quignon F, De Bels F, Koken M, Feunteun J, Ameisen JC, de The H (1998) PML induces a novel caspase-independent death process. Nat Genet 20 : 259-265
8. He LZ, Merghoub T, Pandolfi PP (1999) In vivo analysis of the molecular pathogenesis of acute promyelocytic leukemia in the mouse and its therapeutic implications. Oncogene 18 : 5278-5292
9. Raelson JV, Nervi C, Rosenauer A, Benedetti L, Monczak Y, Pearson M, Pelicci PG, Miller WH, Jr (1996) The PML/ RAR alpha oncoprotein is a direct molecular target of retinoic acid in acute promyelocytic leukemia cells. Blood 88 : 2826-2832
10. Shao W, Fanelli M, Ferrara FF, Riccioni R, Rosenauer A, Davison K, Lamph WW, Waxman S, Pelicci PG, Lo Coco F, Avvisati G, Testa U, Peschle C, Gambacorti-Passerini C, Nervi C, Miller WH, Jr (1998) Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells. J Natl Cancer Inst 90 : 124-133
11. Du C, Redner RL, Cooke MP, Lavau C (1999) Overexpression of wild-type retinoic acid receptor alpha (RARalpha) recapitulates retinoic acid-sensitive transformation of primary myeloid progenitors by acute promyelocytic leukemia RARalpha-fusion genes. Blood 94 : 793-802
12. Grignani F, De Matteis S, Nervi C, Tomassoni L, Gelmetti V, Cioce M, Fanelli M, Ruthardt M, Ferrara FF, Zamir I, Seiser C, Grignani F, Lazar MA, Minucci S, Pelicci PG (1998) Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia. Nature 391 : 815-818
13. Guidez F, Ivins S, Zhu J, Soderstrom M, Waxman S, Zelent A (1998) Reduced retinoic acid-sensitivities of nuclear receptor corepressor binding to PML-and PLZF-RARalpha underlie molecular pathogenesis and treatment of acute promyelocytic leukemia. Blood 91 : 2634-2642
14. Lodie TA, Behre G, Zhang P, Pelicci P, Tenen DG (1998) Expression of the leukemic fusion protein PML/RARα, inhibits C/EBPα DNA binding and blocks granulocytic differentiation (abstract 860). Blood 92[suppl 1]:211a
15. Radomska HS, Huettner CS, Zhang P, Cheng T, Scadden DT, Tenen DG (1998) CCAAT/enhancer binding protein alpha is a regulatory switch sufficient for induction of granulocytic development from bipotential myeloid progenitors. Mol Cell Biol 18 : 4301-4314
16. Zhang DE, Zhang P, Wang ND, Hetherington CJ, Darlington GJ, Tenen DG (1997) Absence of granulocyte colony-stimulating factor signaling and neutrophil development in CCAAT enhancer binding protein alpha-deficient mice. Proc Natl Acad Sci U S A 94 : 569-574
17. Tamayo P, Slonim D, Mesirov J, Zhu Q, Kitareewan S, Dmitrovsky E, Lander ES, Golub TR (1999) Interpreting patterns of gene expression with self-organizing maps: methods and application to hematopoietic differentiation. Proc Natl Acad Sci U S A 96 : 2907-2912
18. Park DJ, Chumakov AM, Vuong PT, Chih DY, Gombart AF, Miller WH, Jr, Koeffler HP (1999) CCAAT/enhancer binding protein epsilon is a potential retinoid target gene in acute promyelocytic leukemia treatment. J Clin Invest 103 : 1399-1408
19. Casini T, Pelicci PG (1999) A function of p21 during promyelocytic leukemia cell differentiation independent of CDK inhibition and cell cycle arrest. Oncogene 18 : 3235-3243
20. Estey EH, Thall PF, Pierce S, Cortes J, Beran M, Kantarjian H, Keating MJ, Andreeff M, Freireich E (1999) Randomized phase II study of fludarabine + cytosine arabinoside + idarubicin +/-all-trans retinoic acid +/-granulocyte colony-stimulating factor in poor prognosis newly diagnosed acute myeloid leukemia and myelodysplastic syndrome. Blood 93 : 2478-2484
21. Purton LE, Bernstein ID, Collins SJ (1999) All-trans retinoic acid delays the differentiation of primitive hematopoietic precursors (lin-c-kit+Sca-1(+)) while enhancing the terminal maturation of committed Granulocyte/Monocyte progenitors. Blood 94 : 483-495
22. Fanelli M, Minucci S, Gelmetti V, Nervi C, Gambacorti-Passerini C, Pelicci PG (1999) Constitutive degradation of PML/RARalpha through the proteasome pathway mediates retinoic acid resistance. Blood 93 : 1477-1481
23. Slack JL, Yu M (1998) Constitutive expression of the promyelocytic leukemia-associated oncogene PML-RARalpha in TF1 cells: isoform-specific and retinoic acid-dependent effects on growth, bcl-2 expression, and apoptosis. Blood 91 : 3347-3356
24. Nervi C, Ferrara FF, Fanelli M, Rippo MR, Tomassini B, Ferrucci PF, Ruthardt M, Gelmetti V, Gambacorti-Passerini C. Diverio D, Grignani F, Pelicci PG, Testi R (1998) Caspases mediate retinoic acid-induced degradation of the acute promyelocytic leukemia PML/RARalpha fusion protein. Blood 92 : 2244-2251
25. Dai J, Weinberg RS, Waxman S, Jing Y (1999) Malignant cells can be sensitized to undergo growth inhibition and apoptosis by arsenic trioxide through modulation of the glutathione redox system. Blood 93 : 268-277
26. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP, Jr (1998) Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med 339 : 1341-1348
27. Ding W, Li YP, Nobile LM, Grills G, Carrera I, Paietta E, Tallman MS, Wiernik PH, Gallagher RE (1998) Leukemic cellular retinoic acid resistance and missense mutations in the PML-RARalpha fusion gene after relapse of acute promyelocytic leukemia from treatment with all-trans retinoic acid and intensive chemotherapy. Blood 92 : 1172-1183
28. Imaizumi M, Suzuki H, Yoshinari M, Sato A, Saito T, Sugawara A, Tsuchiya S, Hatae Y, Fujimoto T, Kakizuka A, Konno T, Iinuma K (1998) Mutations in the E-domain of RAR portion of the PML/RAR chimeric gene may confer clinical resistance to all-trans retinoic acid in acute promyelocytic leukemia. Blood 92 : 374-382
29. Lo Coco F, Diverio D, Falini B, Biondi A, Nervi C, Pelicci PG (1999) Genetic diagnosis and molecular monitoring in the management of acute promyelocytic leukemia. Blood 94 : 12-22
30. Allford S, Grimwade D, Langabeer S, Duprez E, Saurin A, Chatters S, Walker H, Roberts P, Rogers J, Bain B, Patterson K, McKernan A, Freemont P, Solomon E, Burnett A, Goldstone A, Linch D (1999) Identification of the t(15;17) in AML FAB types other than M3: evaluation of the role of molecular screening for the PML/RARalpha rearrangement in newly diagnosed AML. The Medical Research Council (MRC) Adult Leukaemia Working Party. Br J Haematol 105 : 198-207
31. Mandelli F, Diverio D, Avvisati G, Luciano A, Barbui T, Bernasconi C, Broccia G, Cerri R, Falda M, Fioritoni G, Leoni F, Liso V, Petti MC, Rodeghiero F, Saglio G, Vegna ML, Visani G, Jehn U, Willemze R, Muus P, Pelicci PG, Biondi A, Lo Coco F (1997) Molecular remission in PML/ RAR alpha-positive acute promyelocytic leukemia by combined all-trans retinoic acid and idarubicin (AIDA) therapy. Blood 90 : 1014-1021
32. Burnett AK, Grimwade D, Solomon E, Wheatley K, Goldstone AH (1999) Presenting white blood cell count and kinetics of molecular remission predict prognosis in acute promyelocytic leukemia treated with all-trans retinoic acid: result of the Randomized MRC Trial. Blood 93 : 4131-4143
33. Barbui T, Finazzi G, Falanga A (1998) The impact of all-trans-retinoic acid on the coagulopathy of acute promyelocytic leukemia. Blood 91 : 3093-3102
34. Grimwade D, Howe K, Langabeer S, Davies L, Oliver F, Walker H, Swirsky D, Wheatley K, Goldstone A, Burnett A, Solomon E (1996) Establishing the presence of the t(15;17) in suspected acute promyelocytic leukemia: cytogenetic, molecular, and PML immunofluorescence assessment of patients entered into the M.R.C. ATRA trial. Br J Haematol 94 : 557-573
35. Jansen JH, de Ridder MC, Geertsma WM, Erpelinck CA, van Lom K, Smit EM, Slater R, Reijden BA, de Greef GE, Sonneveld P, Lowenberg B (1999) Complete remission of t(11;17) positive acute promyelocytic leukemia induced by all-trans retinoic acid and granulocyte colony-stimulating factor. Blood 94 : 39-45
36. Fenaux P, Chastang C, Chevret S, Sanz M, Dombret H, Archimbaud E, Fey M, Rayon C, Huguet F, Sotto JJ, Gardin C, Makhoul PC, Travade P, Solary E, Fegueux N, Bordessoule D, Miguel JS, Link H, Desablens B, Stamatoullas A, Deconinck E, Maloisel F, Castaigne S, Preudhomme C, Degos L (1999) A randomized comparison of all transretinoic acid (ATRA) followed by chemotherapy and ATRA plus chemotherapy and the role of maintenance therapy in newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 94: 1192-1200
37. Tallman MS, Andersen JW, Schiffer CA, Appelbaum FR, Feusner JE, Ogden A, Shepherd L, Willman CL, Bloomfield CD, Rowe JM, Wiernik PH (1997) All-trans -retinoic acid in acute promyelocytic leukemia. N Engl J Med 337 : 1021-1028
38. Tallman MS (1999) The thrombophilic state in acute promyelocytic leukemia. Semin Thromb Hemost 25 : 209-215
39. Menell JS, Cesarman GM, Jacovina AT, McLaughlin MA, Lev EA, Hajjar KA (1999) Annexin II and bleeding in acute promyelocytic leukemia. N Engl J Med 340 : 994-1004
40. Tallman MS, Kwaan HC (1992) Reassessing the hemostatic disorder associated with acute promyelocytic leukemia. Blood 79 : 543-553
41. Frankel SR, Eardley A, Lauwers G, Weiss M, Warrell RP, Jr (1992) The "retinoic acid syndrome" in acute promyelocytic leukemia. Ann Intern Med 117 : 292-296
42. Hsu HC, Tsai WH, Chen PG, Hsu ML, Ho CK, Wang SY (1999) In vitro effect of granulocyte-colony stimulating factor and all-trans retinoic acid on the expression of inflammatory cytokines and adhesion molecules in acute promyelocytic leukemic cells. Eur J Haematol 63 : 11-18
43. Larson RS, Brown DC, Sklar LA (1997) Retinoic acid induces aggregation of the acute promyelocytic leukemia cell line NB-4 by utilization of LFA-1 and ICAM-2. Blood 90 : 2747-2756
44. De Botton S, Dombret H, Sanz M, Miguel JS, Caillot D, Zittoun R, Gardembas M, Stamatoulas A, Conde E, Guerci A, Gardin C, Geiser K, Makhoul DC, Reman O, de la Serna J, Lefrere F, Chomienne C, Chastang C, Degos L, Fenaux P (1998) Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group. Blood 92 : 2712-2718
45. Head D, Kopecky KJ, Weick J, Files JC, Ryan D, Foucar K, Montiel M, Bickers J, Fishleder A, Miller M (1995) Effect of aggressive daunomycin therapy on survival in acute promyelocytic leukemia. Blood 86 : 1717-1728
46. Estey E, Thall PF, Pierce S, Kantarjian H, Keating M, (1997) Treatment of newly diagnosed acute promyelocytic leukemia without cytarabine. J Clin Oncol 15 : 483-490
47. Sousa AB, Fernandes JP, Ferreira G, Bernardo M, Conduto A, Costa I, Cruz E, Goncalves AJ, Monteiro A, Nunes O, Ribeiro P, Rodrigues AS, Sousa M, Veiga J, Gouveia J (1999) Short-term intensive consolidation therapy after all-trans retinoic acid in acute promyelocytic leukemia. Am J Clin Oncol 22 : 294-297
48. Sanz MA, Martin G, Rayon C, Esteve J, Gonzales M, Diaz-Mediavilla J, Bolufer P, Barragan E, Terol MJ, Gonzales JD, Colomer D, Chillon C, Rivas C, Gomez T, Ribera JM, Borstein R, Roman J, Calasanz MJ, Arias J, Alvarez C, Ramos F, Deben G (1999) A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARα positive acute promyelocytic leukemia. Blood 94 : 3015-3021
49. Kizaki M, Ueno H, Matsushita H, Takayama N, Muto A, Awaya N, Ikeda Y (1997) Retinoid resistance in leukemic cells. Leuk Lymphoma 25 : 427-434
50. Evans GD, Grimwade DJ, (1999) Extramedullary disease in acute promyelocytic leukemia. Leuk Lymphoma 33 : 219-229
51. Bolufer P, Barragan E, Sanz MA, Martin G, Bornstein R, Colomer D, Delgado MD, Gonzalez M, Marugan I, Roman J, Gomez MT, Anguita E, Diverio D, Chomienne C, Briz M (1998) Preliminary experience in external quality control of RT-PCR PML-RAR alpha detection in promyelocytic leukemia. Leukemia 12 : 2024-2028
52. Diverio D, Rossi V, Avvisati G, DeSantis S, Pistilli A, Pane F, Saglio G, Martinelli G, Petti MC, Santoro A, Pelicci PG, Mandelli F, Biondi A, Lo Coco F (1998) Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. Blood 92 : 784-789
53. Lo Coco F, Diverio D, Avvisati G, Petti MC, Meloni G, Pogliani EM, Biondi A, Rossi G, Carlo-Stella C, Selleri C, Martino B, Specchia G, Mandelli F (1999) Therapy of molecular relapse in acute promyelocytic leukemia. Blood 94 : 2225-2229
54. Mologni L, Ponzanelli I, Bresciani F, Sardiello G, Bergamaschi D, Gianni M, Reichert U, Rambaldi A, Terao M, Garattini E (1999) The novel synthetic retinoid 6-[3-adamantyl-4-hydroxyphenyl]-2-naphthalene carboxylic acid (CD437) causes apoptosis in acute promyelocytic leukemia cells through rapid activation of caspases. Blood 93 : 1045-1061
55. Shiohara M, Dawson MI, Hobbs PD, Sawai N, Higuchi T, Koike K, Komiyama A, Koeffler HP (1999) Effects of novel RAR-and RXR-selective retinoids on myeloid leukemic proliferation and differentiation in vitro. Blood 93 : 2057-2066
56. Estey EH, Giles FJ, Kantarjian H, O'Brien S, Cortes J, Freireich EJ, Lopez-Berestein G, Keating M (1999) Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Blood 94 : 2230-2235
57. Gallagher RE (1998) Arsenic - new life for an old potion. N Engl J Med 339 : 1389-1391
58. Wang ZG, Rivi R, Delva L, Konig A, Scheinberg DA, Gambacorti-Passerini C, Gabrilove JL, Warrell RP, Jr, Pandolfi PP (1998) Arsenic trioxide and melarsoprol induce programmed cell death in myeloid leukemia cell lines and function in a PML and PML-RARalpha independent manner. Blood 92 : 1497-1504
59. Rousselot P, Labaume S, Marolleau JP, Larghero J, Noguera MH, Brouet JC, Fermand JP (1999) Arsenic trioxide and melarsoprol induce apoptosis in plasma cell lines and in plasma cells from myeloma patients. Cancer Res 59 : 1041-1048
60. Li YM, Broome JD (1999) Arsenic targets tubulins to induce apoptosis in myeloid leukemia cells. Cancer Res 59 : 776-780
61. Sternsdorf T, Puccetti E, Jensen K, Hoelzer D, Will H, Ottmann OG, Ruthardt M (1999) PIC-1/SUMO-1-Modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia. Mol Cell Biol 19 : 5170-5178
62. Muller S, Matunis MJ, Dejean A (1998) Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J 17 : 61-70
63. Koken MH, Daniel MT, Gianni M, Zelent A, Licht J, Buzyn A. Minard P, Degos L, Varet B, de The H (1999) Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient. Oncogene 18 : 1113-1118
64. Gianni M, Koken MH, Chelbi-Alix MK, Benoit G, Lanotte M, Chen Z, de The H (1998) Combined arsenic and retinoic acid treatment enhances differentiation and apoptosis in arsenic-resistant NB4 cells. Blood 91 : 4300-4310
65. Lallemand-Breitenbach V, Guillemin MC, Janin A, Daniel MT, Degos L, Kogan SC, Bishop JM, de The H (1999) Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia. J Exp Med 189 : 1043-1052
66. Rego E, He LZ, Wang Z-G, Peruzzi D, Warrell RP, Pandolfi PP (1998) Therapeutic trials with arsenic trioxide (AsO3) and retinoic acid in PML-RARa transgenic mice as models of APL (abstract 1663). Blood 92[suppl 1]:335a
67. Sobulo OM, Borrow J, Tomek R, Reshmi S, Harden A, Schlegelberger B, Housman D, Doggett NA, Rowley JD, Zeleznik-Le NJ (1997) MLL is fused to CBP, a histone acetyltransferase, in therapy-related acute myeloid leukemia with a t(11;16)(q23;p13.3). Proc Natl Acad Sci U S A 94 : 8732-8737
68. Borrow J, Stanton VP, Jr, Andresen JM, Becher R, Behm FG, Chaganti RS, Civin CI, Disteche C, Dube I, Frischauf AM, Horsman D, Mitelman F, Volinia S, Watmore AE, Housman DE (1996) The translocation t(8;16)(p11;p13) of acute myeloid leukaemia fuses a putative acetyltransferase to the CREB-binding protein. Nat Genet 14 : 33-41
69. Carapeti M, Aguiar RC, Goldman JM, Cross NC (1998) A novel fusion between MOZ and the nuclear receptor coactivator TIF2 in acute myeloid leukemia. Blood 91 : 3127-3133
70. Warrell RP, Jr, He LZ, Richon V, Calleja E, Pandolfi PP (1998) Therapeutic targeting of transcription in acute promyelocytic leukemia by use of an inhibitor of histone deacetylase. J Natl Cancer Inst 90 : 1621-1625
71. He LZ, Guidez F, Tribioli C, Peruzzi D, Ruthardt M, Zelent A. Pandolfi PP (1998) Distinct interactions of PML-RARα and PLZF-RARα with co-repressors determine differential responses to RA in APL. Nat Genet 18 : 126-135
72. Wang J, Saunthararajah Y, Redner RL, Liu JM (1999) Inhibitors of histone deacetylase relieve ETO-mediated repression and induce differentiation of AML1-ETO leukemia cells. Cancer Res 59 : 2766-2769